The purpose of this study is to assess the prevalence of veterans with major depressive disorder (MDD) who are being treated with a medication that has current Clinical Pharmacogenetics Implementation Consortium (CPIC) or Pharmacogenomics Knowledgebase (PharmGKB) actionable recommendations that have a pharmacogenomic variation that impacts the safety or efficacy of the subject medication.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
First telehealth appointment: 1. Pharmacogenomics education and informed consent 2. Medical history 3. Sample collection Second telehealth appointment: 1. Results of pharmacogenomic testing 2. Utility and limitations of pharmacogenomic testing 3. Patient-specific potential impacts on current or future medication therapies 4. Answering of patient questions 5. Referral to mental health provider(s) for treatment-specific recommendations
Tuscaloosa VAMC
Tuscaloosa, Alabama, United States
Rate of pharmacogenomic variation with actionable recommendations for medications currently utilized
A medication history will be conducted at enrollment to ensure patient meets criteria for enrollment. Patients will provide a saliva sample at this timepoint. The rate of pharmacogenomic variation will be calculated based on current medications at enrollment; however, the pharmacogenomic screening panel may take up to 6 weeks to return to the patient and investigator.
Time frame: At enrollment
Rate of pharmacogenomic variation with actionable recommendations for all actionable medications
Time frame: At enrollment
Mental health disease state control/progression utilizing disease state-specific validated tools
Validated, disease state-specific tools will be utilized to assess control or progression. Specifically, depression control will be assessed utilizing PHQ-9 as documented within the chart. This will be assessed via retrospective chart review.
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Medication-related costs
Claims data will be used to assess medication-related costs at specific time points.
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Medication-related adverse events
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Number of primary care, mental health provider, mental health pharmacist, specialist, and emergency room visits and hospitalizations
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patient reported medication adherence and reasons for non-adherence
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Patient reported reasons for non-adherence
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Number of pharmacogenomic recommendations made and accepted
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Type of pharmacogenomic recommendations made and accepted
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Number of non-pharmacogenomic recommendations made and accepted
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review
Type of non-pharmacogenomic recommendations made and accepted
Time frame: 3-, 6-, and 12-months post-recommendation via retrospective chart review